Evidence map›Paper›PMID 38871445›Full record

ArticleTobacco control2025

Switching from cigarettes to IQOS: the relative importance of IQOS-associated reward, reinforcement and abstinence relief.

Janet Audrain-McGovern, E Paul Wileyto, Olivia Klapec, Fodie Koita, Andrew A Strasser

Registry-linked trialAbstract readClinical Trial, Phase I
In one paragraph

Article in Tobacco control, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05076708 (The Effects of IQOS Use on Cigarette Smoking Behaviors), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05076708 early_phase1completednot on this map

The Effects of IQOS Use on Cigarette Smoking Behaviors

TypeinterventionalSponsorUniversity of PennsylvaniaRan2021 to 2024Enrolled102ConditionsSmoking, Cigarette Smoking, Tobacco UseArmsIQOS
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Janet Audrain-McGovernDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA audrain@pennmedicine.upenn.edu.ORCID 0000-0003-1661-5854
E Paul WileytoBiostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Olivia KlapecDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Fodie KoitaDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Andrew A StrasserDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Funding

The Effects of IQOS Use on Cigarette Smoking BehaviorR01CA260448 · NCI · UNIVERSITY OF PENNSYLVANIA · PI AUDRAIN-MCGOVERN, JANET E · 2021 to 2023
$1.4M
NCI NIH HHS R01 CA260448
6 · The paper itself

Abstract

introductionThis study investigated whether IQOS, a heated tobacco product, can fully substitute for combustible cigarettes and the factors that promote substitution.

methodsAdults who smoked cigarettes daily (N=90; 21-65 years) completed a baseline ad-lib smoking period (days 1-5), two laboratory visits (days 6-7) and a 2-week period where they were instructed to switch from smoking cigarettes to using IQOS 3.0 (days 8-21). Mixed-effect modelling estimated the changes in cigarettes per day (CPD) and the percentage of baseline CPD substituted by HeatSticks during the switch period. Predictors included IQOS-associated subjective reward, relative reinforcing value, craving relief and withdrawal relief.

resultsParticipants reduced their CPD to about 30% of their baseline smoking rate by the end of the 14-day switch period (p<0001). A lower versus higher reinforcing value of smoking relative to IQOS (RRV; break point <5 vs ≥5) predicted greater reductions in CPD (β=-1.31 (95% CI -2.35 to -0.27) p=0.013). Initially, IQOS use was 72% of the baseline smoking rate (β=71.64 (95% CI 42.79 to 100.48) p<0.0001) and climbed by 0.8% per day (β=0.82 (95% CI 0.01 to 1.64) p=0.05), for an average substitution rate of 83%. The subjective reward of IQOS was the only predictor of a higher substitution rate (β=4.26 (95% CI 1.03 to 7.50) p=0.01).

conclusionsIQOS fully substituted for cigarettes in ~20% of people who were not immediately interested in quitting smoking while the remainder significantly reduced their smoking. Positive reinforcing effects of IQOS foster use and the transition away from combustible cigarettes. TRIAL REGISTRATION NUMBER: NCT05076708.

Indexed as

Cigarette SmokingReinforcement, PsychologyRewardSmokingSmoking CessationTobacco ProductsAdultAgedCravingFemaleHumansMaleMiddle AgedYoung AdultHarm ReductionNicotineNon-cigarette tobacco products

Identifiers

PMID38871445
PMCPMC11638403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.